Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|May 8, 2013
Roche Engineer wins iPad at INTERPHEX
Author(s)Paul Welitzkin
Roche Engineer wins iPad at INTERPHEX
Advertisement
At the INTERPHEX show in New York last month where Pharmaceutical Technology/BioPharm International magazines and Dun & Bradstreet Credibility Corp. launched the Pharmaceutical Technology/BioPharm International Marketplace, a contest was held to give away a free iPad mini.
The lucky winner was Ralph Mehne, an engineer at Roche Molecular Systems in New Jersey.
“I have never won a contest before this,” said Mehne, who has worked in engineering at Roche for the past 16 years. Before that, he was an engineer for a water/wastewater equipment company.
One of Mehne’s hobbies is photography and he said the iPad will get plenty of use.
“I really enjoy photography and since I have a digital camera with a three-inch screen, I will be able to download my pictures to the iPad and make adjustments instantly while I’m still in the field.”
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement